目次

Table of Content

1. Introduction To PROTAC Technology
1.1 Overview Of PROTAC Technology
1.2 Development and Evolution of PROTACs

2. PROTAC Therapies Potential In Cancer Therapeutics
2.1 Importance As Targeted Therapy
2.2 Comparison With Conventional Treatment Methods

3. Clinical Overview of PROTAC Technology
3.1 Components Of PROTAC Molecules
3.2 Mechanism Of Action

4. Global PROTAC Drug Market Trends Insight
4.1 Current Market Overview
4.2 Future Clinical and Commercial Opportunities

5. Global PROTAC Drug Market Trends By Region
5.1 US
5.2 South Korea
5.3 China

6. Global PROTAC Drugs Clinical Trials Insight Overview
6.1 By Company
6.2 By Country
6.3 By Patient Segment
6.4 By Phase
6.5 By Orphan and Fast Track Status

7. Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III

8. Global PROTAC Drug Market Trends By Indication
8.1 Cancer
8.2 Infectious Diseases
8.3 Neurodegenerative diseases
8.4 Autoimmune and Inflammatory Diseases
8.5 Cardiovascular Diseases

9. PROTAC Technology Platforms

10. Global PROTAC Drugs Market Dynamics and Outlook
10.1 Drivers and Opportunities
10.2 Challenges and Restraints

11. Competitive Landscape
11.1 Arvinas
11.2 Axter Therapeutics
11.3 Beactica
11.4 BioTheryX
11.5 EnhancedBio
11.6 Suzhou Kintor Pharmaceuticals
11.7 Monte Rosa Therapeutics
11.8 TYK Medicine
11.9 Ubix Therapeutics
11.10 Uppthera

List of Figures
Figure 1-1: PROTACs - Evolution Across Generations
Figure 1-2: PROTACs - Major Developmental Milestones Over The Years
Figure 2-1: PROTACs - Advantages As Cancer Target Therapy
Figure 3-1: PROTAC - Typical Structure
Figure 3-2: PROTACs - Mechanism Of Action
Figure 4-1: Global - PROTA Therapy Market Size: First 12 Month and First 5 Years Since Approval, (US$ Million)
Figure 6-1: Global - Number of PROTAC Drugs Clinical Trials By Company, 2024
Figure 6-2: Global - Number Of PROTAC Drugs In Clinical Trials By Country, 2024
Figure 6-3: Global - Number Of PROTAC Drugs In Clinical Trials By Patient Segment, 2024
Figure 6-4: Global - Number Of PROTAC Drugs In Clinical Trials By Phase, 2024
Figure 6-5: Global - Fast Track and Orphan Designated PROTAC Drugs In Clinical Trials, 2024
Figure 8-1: Bavdegalutamide Phase I/II (NCT03888612) Study - Initiation and Completion Year
Figure 8-2: Bavdegalutamide Phase I (NCT05177042) Study - Initiation and Completion Year
Figure 8-3: Vepdegestrant Phase I/II (NCT04072952) Study - Initiation and Completion Year
Figure 8-4: VERITAC-2 Phase III (NCT05654623) Study - Initiation and Completion Year
Figure 8-5: VERITAC-3 Phase III (NCT05909397) Study - Initiation and Completion Year
Figure 8-6: I-SPY-2 Phase II (NCT01042379) Study - Initiation and Completion Year
Figure 8-7: ARV-393 Phase I (NCT06393738) Study - Initiation and Completion Year
Figure 8-8: ADVANTA Phase II (NCT06058156) Study - Initiation and Completion Year
Figure 8-9: ZEN Phase II (NCT06028230) Study - Initiation and Completion Year
Figure 9-1: PROTACandreg; Discovery Engine - Arvinas
Figure 9-2: Degraducer Technology - Ubix Therapeutics
Figure 9-3: SpeedUPP Platform - UPPTHERA
Figure 9-4: DaTProD Platform - HealZen Therapeutics
Figure 10-1: Global PROTAC Drugs Market - Drivers and Opportunities
Figure 10-2: Global PROTAC Drugs Market - Challenges and Restraints

List of Tables
Table 2-1: Comparison of PROTACs With Conventional Therapies
Table 6-1: Cancer - Clinical Trials Assessing ARV-471